AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Healthcare
Singular Health Partners with Miami Clinic for 3D Imaging Breakthrough
November 20, 2024 01:34 PM AEDT| By Team Kalkine MediaHighlights,Singular Health announces partnership with Miami-based health clinic,.,Focus on advancing its 3Dicom technology through a commercial pilot,.,Partnership includes A$500,000 equity investment from Provider Network Solutions (PNS),.,Singular...
Biotron Limited Rolls Out New Shares on ASX
November 19, 2024 04:52 PM AEDT| By Team Kalkine MediaHighlights:,Biotron Limited issued 20,751 fully paid ordinary shares on the ASX.,The share issuance results from the exercise of options and conversion of convertible securities.,The move marks a significant step in Biotron's ongoing capital manageme...
Sonic Healthcare Ltd (ASX: SHL) Up 4% After AGM Update
November 19, 2024 01:18 PM AEDT| By Team Kalkine MediaHighlights:,Sonic Healthcare (ASX: SHL) shares rise 4% to $27.30 after providing key updates during its AGM.,The company reported $9 billion in FY24 revenue, with non-COVID-related sales up 16%.,Sonic also raised its dividend by 2%, reflecting strong...
Tryptamine Therapeutics Readies Phase 2 Trials for Psilocin Therapy
November 19, 2024 12:40 PM AEDT| By Team Kalkine MediaHighlights,Tryptamine Therapeutics progresses to Phase 2 clinical trials for TRP-8803,.,TRP-8803,demonstrated,enhanced safety and efficiency in Phase 1b studies,.,The IV-infusion formulation offers key advantages over traditional oral dosing,.,Trypta...
CSL Shares Shed 10% in a Month: Market Disruption a Possible Factor
November 18, 2024 06:31 PM AEDT| By Team Kalkine MediaHighlights:,CSL Ltd shares have experienced a 9.77% decline over the past month.,The drop in CSL shares aligns with broader selloffs in the healthcare sector, influenced by geopolitical and regulatory concerns.,Despite the decline, CSL has reaffirmed...
CSL Shares Dip Amid Concerns Over RFK Jr’s Vaccine Policies
November 18, 2024 04:07 PM AEDT| By Team Kalkine MediaHighlights,C,SL falls to a six-month low amid vaccine policy uncertainty,.,Broader ASX healthcare sector declines following the nomination,.,Potential impacts on biotechnology and vaccine manufacturers highlighted,.,Australia's leading pharmaceutical...
Amplia Therapeutics Teams Up with Next&Bio for Preclinical Research on Pancreatic Cancer
November 18, 2024 03:14 PM AEDT| By Team Kalkine MediaHighlights,Amplia,Therapeutics partners with,Next&Bio,to evaluate the impact of FAK inhibitors on pancreatic cancer,.,The study explores potential,synergy,between,Amplia’s,AMP945 and emerging,kRas,inhibitors,.,Next&Bio,uses advanced patient-derived m...
Radiopharm Theranostics Boosts Prospects with Pancreatic Cancer Imaging Study
November 18, 2024 12:10 PM AEDT| By Team Kalkine MediaHighlights,Radiopharm,Theranostics,’ imaging drug RAD 301 shows promising results for pancreatic cancer detection,.,A published study supports its ability to distinguish primary carcinoma and metastases effectively,.,RAD 301 achieves a high tumor-to-...
InhaleRX (ASX:IRX) Gains Phase 2 Approval for Non-Opioid Cancer Pain Therapy
November 15, 2024 02:54 PM AEDT| By Team Kalkine MediaHighlights,InhaleRX,receives approval for Phase 2 trial to explore non-opioid cancer pain therapy.,IRX-211 aims to offer a safe, fast-acting pain relief alternative for cancer patients.,Non-opioid breakthrough could address a significant market deman...
Opthea’s Vision Therapy Gains Significant R&D Funding Boost
November 15, 2024 02:25 PM AEDT| By Team Kalkine MediaHighlights,Opthea,receives significant R&D tax incentive from the Australian Taxation Office,.,Funding supports,sozinibercept,development for wet age-related macular degeneration (AMD),.,Phase 3 trials underway, aiming to improve outcomes for severe...
Recce Pharmaceuticals (ASX:RCE) Secures $6.75 Million R&D Tax Incentive Rebate
November 14, 2024 04:39 PM AEDT| By Team Kalkine MediaHighlights,Recce Pharmaceuticals receives a significant $6.75 million R&D tax rebate.,Funds boost Recce’s development of advanced synthetic anti-infectives.,Rebate supports company’s international and domestic R&D initiatives.,Recce Pharmaceuticals (...
Neuren Pharmaceuticals Shares Surge 8.4% on Announcement of AU$50Mn Share Buyback Program
November 14, 2024 12:21 PM AEDT| By Team Kalkine MediaHighlights,Neuren Pharmaceuticals’ shares jumped 8.4% to AU$17.94, marking the highest level since August and making it the top gainer on the ASX 200 index.,The company launched a share buyback program, aiming to repurchase up to 3 million shares wit...
Recce Pharmaceuticals Bolstered by R&D Rebate and Advances in Clinical Trials
November 14, 2024 12:03 PM AEDT| By Team Kalkine MediaHighlights,Recce Pharmaceuticals received over A$6.75 million as an R&D Tax Incentive rebate.,Funds to support global R&D initiatives, including upcoming clinical trials.,Rebate reinforces Australia's commitment to life science innovation.,Recce Phar...
Can BlinkLab’s Tech Revolutionize Autism and ADHD Diagnosis?
November 13, 2024 03:52 PM AEDT| By Team Kalkine MediaHighlights,BlinkLab,collaborates with Monash University on a groundbreaking autism and ADHD study.,The study,utilizes,eye-tracking tech to,identify,unique markers in children with autism and ADHD.,MAGNET project to explore data-driven methods for mor...
Is Paragon Care (ASX:PGC) Enhancing Performance with Smart Financial Strategies?
November 13, 2024 03:21 PM AEDT| By Team Kalkine MediaHighlights,Paragon Care’s stock rose by 11% recently, drawing attention to its financial growth.,ROE highlights Paragon Care’s profitability and reinvestment approach.,Despite a low ROE, Paragon Care’s earnings have grown significantly.,Paragon Care...
IDT Australia’s Takeover Offer from Mynd Falls Through Amid Due Diligence Concerns
November 13, 2024 03:20 PM AEDT| By Team Kalkine MediaHighlights,Proposed,Myndbio,acquisition of IDT Australia canceled after due diligence.,Myndbio,didn’t,finalize,an updated proposal, leaving IDT to end discussions.,IDT grapples with challenges in the cannabis market and aims for future recovery.,IDT...
Will Orthocell's Nerve Repair Product Remplir™ Make Waves in the US Market?
November 12, 2024 06:21 PM AEDT| By Team Kalkine MediaHighlights,Orthocell,eyes the US,$1.6 billion,nerve repair market with,Remplir,™ launch.,New leadership to drive growth as FDA approval expected in early 2025.,Expansion backed by A$35 million in funding to target global markets.,Orthocell (ASX: OCC)...
Pro Medicus (ASX:PME) Stands Out with Strong Earnings Growth and Insider Alignment
November 12, 2024 06:15 PM AEDT| By Team Kalkine MediaHighlights,Pro Medicus has seen substantial earnings growth, enhancing shareholder value.,Insiders hold a significant share, aligning their interests with those of other shareholders.,The company’s CEO compensation,remains,moderate, reflecting respon...
Actinogen Secures $9M R&D Rebate to Advance Alzheimer’s Therapy Trial
November 12, 2024 03:07 PM AEDT| By Team Kalkine MediaHighlights,Actinogen,Medical receives a $9 million R&D tax rebate.,Funds support Alzheimer’s therapy trial with 220 participants.,Financial backing ensures operations through mid-2026.,Actinogen Medical Ltd (ASX:ACW) has recently received a substanti...
Recce Pharmaceuticals Advances in Antibiotic Resistance with Trial Approval
November 11, 2024 06:57 PM AEDT| By Team Kalkine MediaHighlights,Recce Pharmaceuticals receives ethics approval for Phase 3 clinical trial in Indonesia.,Company advances towards addressing antibiotic resistance with RECCE 327.,Indonesian clinical trial aims to combat diabetic foot infections.,Recce Phar...
Advertise your brand on Kalkine Media